1. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874
2. Albain K, Barlow W, O’Malley F, Siziopikou K, Yeh I-T, Ravdin P, Lew D, Farrar W, Burton G, Ketchel S, Cobau C, Levine E, Ingle J, Pritchard K, Linchter A, Schneider D, Abeloff M, Henderson IC, Norton L, Hayes D, Green S, Livingston R, Martino S, Osborne CK, Allred DC, for the Breast Cancer Intergroup of North America (2004) Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88 (Suppl 1):abstract 37
3. Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27–36
4. Apantaku LM (2000) Breast cancer diagnosis and screening. Am Fam Physician 62:596
5. Arora NK, Gustafson DH, Hawkins RP, McTavish F, Cella DF, Pingree S, Mendenhall JH, Mahvi DM (2001) Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. Cancer 92:1288–1298